Ardelyx Inc reports results for the quarter ended March 31 - Earnings Summary

Ardelyx

02/05/2025 05:07

Ardelyx Inc ARDX.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -11 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -21 cents to -4 cents per share.

Revenue rose 61% to $74.11 million from a year ago; analysts expected $78.80 million.

Ardelyx Inc's reported EPS for the quarter was a loss of 17 cents​.

The company reported a quarterly loss of $41.14 million.

Ardelyx Inc shares had risen by 12.1% this quarter and gained 8.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ardelyx Inc is $11.00

This summary was machine generated from LSEG data May 2 at 04:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.11
-0.17
Missed
Dec. 31 2024
0.00
0.02
Beat
Sep. 30 2024
-0.05
0.00
Beat
Jun. 30 2024
-0.11
-0.07
Beat